Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELI-002 2P · 1 trial · 12 indications
The safety of ELI-002 was monitored through adverse events, including those considered related to treatment by the investigator
| Arm | Type | Description |
|---|---|---|
| ELI-002 2P Cohort 1 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via subcutaneous (SC) injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 2 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 3 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 4 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (5.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 5 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (10.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| Name | Type | Description |
|---|---|---|
| ELI-002 2P | DRUG | Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
Inclusion Criteria: * KRAS/NRAS mutated (G12D or G12R) solid tumor * Positive for circulating tumor DNA (ctDNA) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable * Screening CT is negative for recurrent disease...
ELI-002 2P is an investigational small molecule being studied for the treatment of minimal residual disease in patients with KRAS-mutated cancers, including pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, ovarian cancer, cholangiocarcinoma, bile duct cancer, and gallbladder carcinoma.
ELI-002 2P targets cancers with KRAS G12D, KRAS G12R, NRAS G12D, and NRAS G12R mutations. It is designed to address minimal residual disease, which refers to the small number of cancer cells that remain after treatment and can lead to relapse.
ELI-002 2P is being developed by Elicio Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol ELTX. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with KRAS-mutated solid tumors.
ELI-002 2P is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, tolerability, and potential efficacy in treating minimal residual disease in KRAS-mutated cancers.
ELI-002 2P has been studied in one completed Phase 1 clinical trial, registered as NCT04853017. This trial enrolled 25 participants with KRAS-mutated pancreatic ductal adenocarcinoma and other solid tumors, and was conducted in the United States with participants aged 18 years and older.
ELI-002 2P is a version of the investigational drug ELI-002. The clinical trial NCT04853017, titled 'A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors,' evaluated ELI-002 in patients with minimal residual disease and various KRAS-mutated cancers.